• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种在监测依斯的明治疗过程中实时测量乙酰胆碱酯酶活性的患者端技术。

A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.

作者信息

Mosca A, Onelli E, Rosti E, Paleari R, Luzzana M, Imbimbo B P

机构信息

Department of Sciences and Biomedical Technologies, University of Milan, Italy.

出版信息

Ther Drug Monit. 1995 Jun;17(3):230-8. doi: 10.1097/00007691-199506000-00004.

DOI:10.1097/00007691-199506000-00004
PMID:7624918
Abstract

Rapid and reliable measurement of acetylcholinesterase (AChE) activity is of crucial importance to the pharmacodynamic monitoring of anticholinesterase drugs. A new assay has been developed to measure AChE from 10 microliter samples of capillary blood. AChE activity was calculated from the change in pH of the reaction medium caused by the hydrolysis of acetylcholine and measured with a highly sensitive differential pH apparatus (CL-10, Eurochem, Rome, Italy). Interference by butyrylcholinesterase was eliminated by a specific inhibitor, quinidine sulfate. The assay lasts 1 min. The coefficient of variation (CV) for replicated measurements was 2.8% (3267 U/L, n = 33). Linearity ranged from 0 to 10,000 U/L. The correlation coefficient between the new technique and Ellman's colorimetric method on washed erythrocytes was r = 0.987 (y = 1.299x - 63, n = 29). The correlation coefficient between assays on capillary and venous samples was r = 0.979 (y = 0.974x + 174, n = 47). A cross-laboratory validation study was performed in 10 centers using glycerol-stabilized hemolysates with normal and reduced AChE activity. Samples were assayed in triplicate. The within- and between-laboratory CVs for samples with normal AChE activity (6,018 U/L) were 2.2 and 8.1%, respectively. The new method was applied to a double-blind, placebo-controlled multicenter study of eptastigmine in Alzheimer patients and proved to be a simple, noninvasive, rapid, and reliable method for pharmacodynamic monitoring of this drug.

摘要

快速、可靠地测定乙酰胆碱酯酶(AChE)活性对于抗胆碱酯酶药物的药效学监测至关重要。现已开发出一种新的检测方法,用于测定10微升毛细血管血样中的AChE。通过乙酰胆碱水解引起的反应介质pH变化来计算AChE活性,并使用高灵敏度差分pH仪(CL - 10,Eurochem,意大利罗马)进行测量。通过特定抑制剂硫酸奎尼丁消除丁酰胆碱酯酶的干扰。该检测耗时1分钟。重复测量的变异系数(CV)为2.8%(3267 U/L,n = 33)。线性范围为0至10,000 U/L。新技术与洗过红细胞的埃尔曼比色法之间的相关系数为r = 0.987(y = 1.299x - 63,n = 29)。毛细血管样本和静脉样本检测之间的相关系数为r = 0.979(y = 0.974x + 174,n = 47)。在10个中心进行了一项跨实验室验证研究,使用具有正常和降低AChE活性的甘油稳定溶血产物。样本进行了三次检测。正常AChE活性(6,018 U/L)样本的实验室内和实验室间CV分别为2.2%和8.1%。该新方法应用于一项关于艾斯他明治疗阿尔茨海默病患者的双盲、安慰剂对照多中心研究,结果证明它是一种用于该药物药效学监测的简单、无创、快速且可靠的方法。

相似文献

1
A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.一种在监测依斯的明治疗过程中实时测量乙酰胆碱酯酶活性的患者端技术。
Ther Drug Monit. 1995 Jun;17(3):230-8. doi: 10.1097/00007691-199506000-00004.
2
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.艾斯他明用于阿尔茨海默病的多剂量安全性试验及红细胞胆碱酯酶的药效学观察
Life Sci. 1995;56(5):319-26. doi: 10.1016/0024-3205(94)00954-6.
3
Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.依替斯的明:十年药理学、毒理学、药代动力学及临床研究
CNS Drug Rev. 2001 Winter;7(4):369-86. doi: 10.1111/j.1527-3458.2001.tb00205.x.
4
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.卡巴拉汀在阿尔茨海默病患者中的药效学活性与认知效应之间的关系。卡巴拉汀研究组。
Clin Pharmacol Ther. 1996 Aug;60(2):218-28. doi: 10.1016/S0009-9236(96)90138-1.
5
Acetylcholinesterase assay may predict cognitive response of Alzheimer patients to eptastigmine treatment.乙酰胆碱酯酶测定可能预测阿尔茨海默病患者对艾斯能治疗的认知反应。
Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):809-10. doi: 10.1007/s002280050556.
6
Maximum tolerated dose and pharmacodynamics of eptastigmine in elderly healthy volunteers.老年健康志愿者中依他斯的明的最大耐受剂量及药效学
J Clin Pharmacol. 1998 Jul;38(7):610-7. doi: 10.1002/j.1552-4604.1998.tb04467.x.
7
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.艾斯的明治疗阿尔茨海默病患者的疗效和安全性。
Neurology. 1999 Mar 10;52(4):700-8. doi: 10.1212/wnl.52.4.700.
8
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.胆碱酯酶抑制剂的药效动力学表明,对于长期使用快速可逆抑制剂治疗的患者,可加用低剂量的碳酰化抑制剂进行辅助治疗。
J Alzheimers Dis. 2014;39(2):423-40. doi: 10.3233/JAD-130845.
9
Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.艾斯的明治疗阿尔茨海默病两年。艾斯的明研究组。
Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):139-47. doi: 10.1159/000017114.
10
Pharmacodynamic monitoring of eptastigmine in capillary blood.卡巴拉汀在毛细血管血中的药效学监测。
Eur J Clin Pharmacol. 1996;50(5):425-7. doi: 10.1007/s002280050135.

引用本文的文献

1
The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis.结核病中系统性炎症、氧化应激与组织重塑的相互作用。
Antioxid Redox Signal. 2021 Feb 20;34(6):471-485. doi: 10.1089/ars.2020.8124. Epub 2020 Jun 19.
2
Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.依替斯的明:十年药理学、毒理学、药代动力学及临床研究
CNS Drug Rev. 2001 Winter;7(4):369-86. doi: 10.1111/j.1527-3458.2001.tb00205.x.